Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
319.4 INR | +1.25% | +4.89% | +27.96% |
May. 24 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
May. 24 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
Sales 2024 | 148B 1.78B | Sales 2025 * | 161B 1.94B | Capitalization | 381B 4.59B |
---|---|---|---|---|---|
Net income 2024 | 10.22B 123M | Net income 2025 * | 9.43B 114M | EV / Sales 2024 | 2.14 x |
Net Debt 2024 * | 139B 1.68B | Net Debt 2025 * | 131B 1.58B | EV / Sales 2025 * | 3.18 x |
P/E ratio 2024 |
30.9
x | P/E ratio 2025 * |
41.6
x | Employees | 16,545 |
Yield 2024 * |
0.46% | Yield 2025 * |
0.28% | Free-Float | 37.18% |
Latest transcript on Biocon Limited
1 day | +1.25% | ||
1 week | +4.89% | ||
Current month | +7.00% | ||
1 month | +9.53% | ||
3 months | +16.99% | ||
6 months | +35.73% | ||
Current year | +27.96% |
Managers | Title | Age | Since |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
Chairman | 71 | 78-11-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 78-11-28 | |
Director/Board Member | 69 | 99-12-31 | |
Director/Board Member | 60 | 18-07-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 6 M€ | +6.07% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 319.4 | +1.25% | 31,341,050 |
24-05-23 | 315.5 | +2.45% | 10,367,030 |
24-05-22 | 308 | +0.11% | 3,666,833 |
24-05-21 | 307.6 | +1.00% | 4,862,961 |
24-05-18 | 304.6 | -0.43% | 1,158,358 |
Delayed Quote NSE India S.E., May 24, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.96% | 4.59B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- BIOCON Stock